Skip to main content
. 2014 May 24;4(Suppl 3):S112–S121. doi: 10.1016/j.jceh.2014.03.048

Table 1.

Cumulative Survival Following Trans-arterial Chemo-embolization in Advanced Hepatocellular Carcinoma.

Study
Number of patients
Survival (%)
1 year 2 years
TACE {Gelfoam powder, doxorubicin [50 mg]} Pelletier etal71 (J Hepatol, 1990) 21 24 NR
TACE {Gelfoam particles, cisplatin [70 mg]} Group d'Etude de Traitment du Carcinome He'patocellulare30 (N Engl J Med, 1995) 50 62 38
TACE {Gelfoam, cisplatin [2 mg/kg]} Pelletier et al75 (J Hepatol, 1998) 37 51 24
TACE {Gelfoam, cisplatin [maximum 30 mg]} Lo et al31 (Hepatology, 2002) 40 57 31
TACE {Gelfoam, doxorubicin [25–75 mg/m2] Llovet et al13 (Lancet, 2002) 40 82 63
TACE {Lipiodol, anticancer agent, gelatin sponge} Takayasu et al19 (Gastroenterology, 2006) 8510 82 47 (3 years)
TACE {Lipodol, Mitomycin C 10 mg} Herber et al74 (Rofo, 2007) 94 71.6 33.9
TACE {doxorubicin 50 mg, cisplatin 100 mg, 10–20 ml of lipiodol, gelfoam} Paul et al76 (Indian J Radiol Imaging, 2011) 71 60.8 34.4

NR = not reported.